Progesterone versus progestin in menopause therapy: names are not a safety ranking

Progesterone is a particular hormone; a progestin is a medicine with progesterone-like activity, and the terms are not a built-in “safe versus unsafe” ranking. In menopausal hormone therapy, the key clinical question is usually whether a person using systemic estrogen who has a uterus needs an appropriate second hormone to reduce endometrial risk. The answer depends on the actual estrogen and progesterone/progestin products and regimen, not on whether a marketing page calls an ingredient “natural.”¹²³

Name the molecule before interpreting the claim

The family word progestogen is often used for substances with progesterone-like effects. Micronized progesterone is progesterone made into a medicine. Medroxyprogesterone acetate is a distinct synthetic progestin. Both may appear in discussions about a menopausal estrogen regimen, but a study or label for one is not automatically evidence for the other.²³

The practical consequence: ask for the exact generic name, brand if relevant, route, and labeled purpose. “Bioidentical progesterone” may refer to an FDA-approved product or to an entirely different preparation. The adjective does not identify a tested delivery system, an FDA-approved indication, or the amount reaching the endometrium.

Why the uterus appears in the conversation

ACOG explains that using estrogen alone when a person has a uterus can increase the risk of endometrial cancer, and that adding a progestin to systemic estrogen lowers that risk. That does not mean everyone considering hormone therapy needs the same two-drug regimen. Uterine status, the form of estrogen and the treatment goal must be established first.¹

The current Prometrium label is unusually specific: its oral progesterone indication includes prevention of endometrial hyperplasia in a postmenopausal woman with a uterus receiving conjugated estrogens. A product-specific label does not prove that any progesterone cream, pellet or alternative schedule provides the same protection. It also does not imply that Prometrium is appropriate for everyone. The product contains peanut oil, an example of why even the inactive ingredients in an exact formulation can matter to a consultation.²

Medroxyprogesterone acetate tablets have their own indications and warnings. Prempro is a separate fixed combination of conjugated estrogens and medroxyprogesterone. A clinician comparing a proposed regimen with data from Prempro should say explicitly when the formulation matches and when it does not. It would be misleading to assign the exact effects observed with one combination to every “progestin,” or to treat use of micronized progesterone as a guarantee that a different combination’s risks disappear.³⁴

Do not let three evidence questions collapse into one

First is the mechanism and product identity question: what is the molecule and how is it delivered? Second is the endometrial protection question: in someone using systemic estrogen with a uterus, what evidence supports the chosen second component and schedule? Third is the overall benefit–risk question: what is known about this exact combination in a population comparable to the person considering it? These questions can have different quality and amounts of evidence.

An internet comparison often skips directly from a chemical description to a claim about long-term breast, vascular or mood outcomes. Such outcomes cannot be ranked just by calling a substance “synthetic” or “body-identical.” Product labels, trial designs, patient populations and observation periods need to be named. When the best evidence is indirect or incomplete, the useful answer says so.

What to bring to a hormone-therapy visit

Bring a list of any current prescription, over-the-counter or compounded hormones, including creams and pellets, rather than only a category name. State whether the uterus and ovaries are present or have been removed, and whether the discussion is about menopausal symptoms, another diagnosis or a different goal. If a clinic offers a “custom” progesterone product, ask whether it is an FDA-approved drug, what source supports its use, and what follow-up is planned. Compounding and approval are not interchangeable terms.

The progesterone-cream guide answers the narrower absorption-and-protection question; the hysterectomy guide explains why anatomy changes the initial decision. This page provides the vocabulary for comparing the actual medicines. Use Treomark’s hormone-therapy provider discovery to find a consultation, then ask that practice to explain the named products and evidence rather than a reassuring class label.